Burosumab, a neutralizing antibody to FGF23, first received United States (US) Food and Drug Administration approval in April 2018, and is indicated for the treatment of XLH in adult and pediatric patients aged 6 months and older [1, 15, 16]. Here, FGF23 is linked to X-linked hypophosphatemia.